All studies
Active not recruitingPHASE3INTERVENTIONAL

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

This clinical trial investigates a new drug combination for men with advanced prostate cancer. Researchers want to see if adding an anti-androgen medicine called apalutamide to standard hormone treatments (abiraterone and prednisone) works better than standard treatment alone at stopping or slowing cancer growth. The study focuses on men with 'metastatic castration-resistant prostate cancer'. This means the cancer has spread outside the prostate to areas like the bones or lymph nodes and has continued to grow despite treatments that lower testosterone levels. Men taking part must not have had chemotherapy for this stage of their disease. Participants will be placed into one of two groups by chance. One group receives apalutamide with standard care, while the other receives standard care plus a dummy pill (placebo). Doctors will monitor participants closely with regular scans, blood tests, and health checks.

At a glance

Status
Active not recruiting
Phase
PHASE3
Sponsor
Aragon Pharmaceuticals, Inc.
Enrolment target
982
Start
26 Nov 2014
Estimated completion
31 Dec 2027

Results

Results from this study

Posted August 2021

Results have been published for this study.

Primary outcome
Radiographic Progression-free Survival (rPFS)
The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\>=) 2 new lesions compared to baseline was observed in less than (\<) 12 weeks from randomization and was confirmed by a second bone scan taken \>=6 weeks later showing \>=2 additional new lesions (a total of \>=4 new lesions compared to baseline), b) the first bone scan with \>=2 new lesions compared to baseline was observed in \>=12 weeks from randomization and the new lesions were verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Full results on the registry

What is this study about?

Prostate cancer often relies on male hormones, such as testosterone, to grow. Standard treatments usually work by lowering these hormone levels or blocking their effects. However, over time, the cancer can find ways to grow even when testosterone levels in the body are very low. When this happens and the cancer has spread to other organs or bones, doctors call it metastatic castration-resistant prostate cancer.

Currently, many men at this stage receive a combination of standard tablets called abiraterone acetate and prednisone, which help block hormone production and control inflammation. In this trial, researchers want to see if adding another targeted hormone drug, apalutamide, can provide a more powerful block against cancer signals and keep the disease under control for longer.

Because this is a Phase 3 trial, it is testing the combination in a large group of patients to confirm whether it is safe and truly more effective than standard treatment. Participants are monitored with regular scans to measure whether the cancer stays stable, shrinks, or grows, helping doctors understand if this approach could become a new standard treatment option in the UK.

Key takeaways

  • Tests whether adding apalutamide to standard hormone pills slows prostate cancer growth.
  • For men whose advanced prostate cancer is growing despite standard hormone therapy.
  • Open to men who have not received chemotherapy for advanced prostate cancer.
  • A computer randomly decides if you get apalutamide or a dummy pill alongside standard care.
  • Participants receive close monitoring through routine blood tests and hospital scans.

Who may be eligible?

This study is open to men aged 18 and over who have been diagnosed with prostate cancer that has spread to other parts of the body, such as the bones or lymph nodes. To take part, your cancer must be showing signs of growing—such as rising PSA levels in blood tests—even though you are currently on hormone therapy that keeps testosterone levels low.

You cannot take part if you have already had chemotherapy for your advanced prostate cancer (although chemotherapy given years earlier alongside initial surgery or radiotherapy may be allowed). You must also be well enough to carry out daily activities and have no history of the cancer spreading to the brain.

Certain medical conditions or medications will also make you ineligible. For example, men who have had specific prior treatments like ketoconazole, who take medicines that increase seizure risks, or who use certain herbal supplements like saw palmetto may not be able to join.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am a man aged 18 or older.
  2. I have been diagnosed with prostate cancer that has spread to my bones or other organs.
  3. My PSA levels or scans show the cancer is progressing despite hormone-lowering therapy.
  4. I have not had chemotherapy for advanced prostate cancer.
  5. I do not have cancer spread to my brain and have no history of seizures.
Answer every question to see your result.

What does participation involve?

Taking part involves taking daily tablets by mouth at home. You will be randomly assigned by a computer to receive either the active medicine (apalutamide) or an identical-looking dummy tablet (placebo), alongside standard abiraterone and prednisone tablets. Neither you nor your hospital doctor will know which group you are in. You will visit the hospital regularly for health checks, blood tests (including PSA checks), and imaging scans such as CT, MRI, or bone scans to track your tumour. The study lasts through three stages: screening checks to confirm suitability, active treatment for as long as it benefits you safely, and a long-term follow-up stage to check on your health over time.

Potential risks and benefits

A potential benefit is that the treatment combination may help keep your cancer from growing for longer than standard care alone, and you will receive regular, close medical monitoring. However, there is no guarantee of personal benefit, and you could receive the placebo instead of apalutamide. Possible risks include side effects from the study tablets, such as fatigue, high blood pressure, skin rashes, joint pain, or stomach upset. Your study doctor will discuss all possible side effects with you before you join. You are completely free to leave the study at any time, and doing so will not affect the standard NHS care you receive.

Locations (173)

  • —
    Verified postcode
    Phoenix, United States
  • —
    Verified postcode
    La Mesa, United States
  • —
    Verified postcode
    Los Angeles, United States
  • —
    Verified postcode
    Modesto, United States
  • —
    Verified postcode
    San Diego, United States
  • —
    Verified postcode
    San Francisco, United States
  • —
    Verified postcode
    Santa Barbara, United States
  • —
    Verified postcode
    Aurora, United States
  • —
    Verified postcode
    Denver, United States
  • —
    Verified postcode
    Jensen Beach, United States
  • —
    Verified postcode
    Lakeland, United States
  • —
    Verified postcode
    New Port Richey, United States

Common questions

What is a placebo and could I receive one?

A placebo is a dummy tablet that looks identical to the study drug but contains no active medicine. In this trial, half the men receive a placebo instead of apalutamide. However, all participants will still receive standard, proven cancer treatments (abiraterone and prednisone).

What does 'chemotherapy-naive' mean?

It simply means that you have not yet received chemotherapy drugs for this advanced stage of your prostate cancer.

Will taking part cost me anything?

No, the study medicines and tests are provided free of charge, and trial organisers often help cover travel costs to and from your hospital visits.

How will the doctors know if the treatment is working?

The team will monitor you with regular blood tests (checking PSA levels) and routine imaging scans, such as bone and CT scans, to see if the tumours are stable or shrinking.

Can I leave the study if I change my mind?

Yes. Joining a clinical trial is entirely voluntary. You can withdraw your consent at any time without giving a reason, and your medical team will continue to offer you the best available standard treatment.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.